Anthem Blue Cross Blue Shield $Varies Settlement for Uncovered Prostate Cancer Proton Beam Therapy

Anthem Blue Cross Blue Shield is facing a class action settlement involving uncovered prostate cancer treatment—specifically proton beam radiation therapy. Proton beam therapy is a high-precision form of radiation treatment that can reduce exposure to surrounding tissues, but coverage decisions can vary widely by insurer and by whether a plan classifies the therapy as medically necessary or falls within its established criteria. According to the settlement notice, eligible people are those who received proton beam radiation therapy for prostate cancer, sought insurance coverage through Anthem, and were denied or otherwise not covered for those treatments. The lawsuit was filed to challenge Anthem’s handling of these coverage requests and to seek refunds or compensation for patients who paid out of pocket—or suffered reimbursement denials—after requesting coverage for proton beam therapy. Class actions like this are significant because they consolidate many similar claims into a single case, making it easier for affected patients to pursue relief and increasing pressure on insurers to apply coverage standards more consistently. The settlement listing signals that Anthem’s dispute over proton beam therapy claims has reached a resolution, with a payout amount labeled “varies” and a deadline for participation by 10/10/26, while proof of treatment and coverage need not be provided in the form described by the notice. Broader implications include ongoing scrutiny of how health plans determine “medical necessity,” manage utilization, and enforce coverage policies for advanced cancer treatments. In the broader industry context, insurers operate under a mix of federal and state rules that can include consumer-protection standards, requirements around coverage determinations, and standards for how plans handle appeals and adverse benefit decisions; although specific obligations depend on plan type and jurisdiction, coverage disputes for high-cost specialty therapies are a recurring theme. Similar cases have emerged across oncology and other specialty care areas where patients argue that insurers undervalued or improperly denied coverage for treatments they believed were clinically appropriate, and this settlement fits that pattern as another example of how disputes over radiation therapy access can drive legal and regulatory attention.